


Congenital Myasthenic Syndrome (CMS) - Golden Retriever Type

<p>Client Name: Lauriaan Morton (LAU002)</p> <p>Client Address: Lauriaan Morton (LAU002) 23 Egret Street Welkom, Free State 9459 South Africa</p> <p>Phone: 0768783024</p> <p>Email: lauriaan@vodamail.co.za</p>	<p>Report No: ZO2025/9673/20250804/#101088</p> <div style="text-align: center;">  </div>
<p>Profile: DG2025/93667</p> <p>Name: Golden Starseed Blue (Mufasa)</p> <p>Breed: Golden Retriever</p>	<p>Species: Canis lupus familiaris / Canine / Dog</p> <p>Microchip #: 972274200143122</p>
<p>Test: [CMS_GR] Congenital Myasthenic Syndrome (CMS) - Golden Retriever Type</p> <p>Results: c.880G>A GG Clear</p>	

Sample Type: Whole Blood (EDTA)	Extraction Method: DNA Extraction: D4069	Test Type: Genetic Health
<p style="color: #c00000;">[CMS_GR] Congenital Myasthenic Syndrome (CMS) - Golden Retriever Type</p>		
<p>Congenital Myasthenic Syndrome is a neuromuscular disorder, with clinical signs of the disease beginning at weaning, resulting in progressive muscle weakness exacerbated by exercise. The gait of affected dogs is often characterized by choppy, increasingly short strides, as well as stiffening of the legs.</p> <p>The condition is caused by a c.880G>A substitution mutation in the collagen-like tail of the asymmetric acetylcholinesterase (COLQ) gene, which results in an amino acid change from glycine to arginine. This change inhibits normal gene function, and is suspected to affect the removal of acetylcholine from the neuromuscular junction, which is required for normal muscle function. The mutation is well characterised in the Golden Retriever.</p> <p>The condition is inherited in an autosomal recessive manner, meaning that the dog must have two copies of the mutation to present with the condition.</p> <p>References: Tsai et al 2019. Congenital Myasthenic Syndrome in Golden Retrievers is associated with a novel COLQ mutation J. Vet. Intern. Med. 2020 (34), 258-265.</p>		

It is the sender's responsibility to ensure the correctness of the information accompanying the samples. In no event shall Inqaba Biotechnical Industries (Pty) Ltd or its divisions be held liable for indirect, substantial or secondary damages of any kind. Results are usually made available within 7-14 days of receipt of samples. Please note that results are only released subject to payment.

Disclaimer:

Whatever is contained in this report is subject to the following:

This report does not disregard the existence of any rare or unknown variant within this gene or other gene(s) that may result in the same or similar trait. Multiple mutations and/or gene(s) may contribute to the overall trait observed.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof (Registration number: 2001/011245/07) accept that the biological specimen(s) provided, originates from the relevant animal(s) indicated on supporting documents received and does not accept responsibility for the downstream effects of incorrect information provided.

It is the responsibility of the client that all biological samples are available at submission or previously submitted and corresponds with all requested samples listed on the sample submission form. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof do not accept responsibility for the effect of any absent samples on the analysis results.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof accept that all genetic profiles and/or samples from external sources are correctly labelled and accurate. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof do not accept responsibility for the effect of any inaccuracies of submitted DNA profiles on the analysis and results.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof shall not be responsible for human and/or technical errors that could not have been foreseen.

This document is solely for the use of the addressee and only in connection for the purpose set out in this document. Inqaba Biotechnical Industries Pty Ltd and the divisions thereof do not assume liability or responsibility to any third party to which this document is disclosed or otherwise made available.

Nothing in this document should be construed as advice to proceed or not to proceed with any specific course of action, as it was not prepared for that purpose.

The DNA profile is based on a preliminary marker panel that is subject to modification pending additional genetic information.

It is the sender's responsibility to obtain permits when sending samples where required.

Inqaba Biotechnical Industries Pty Ltd and the divisions thereof reserve the right to decline testing of samples.

No guarantees are made with regards to turn-around processing time and results, and no liability will be accepted for any delays.